New drug targets cancer spread in first human trial
NCT ID NCT04222413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children aged 12-17 with certain solid tumors. Participants take metarrestin by mouth and are closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metarrestin (ML-246)
What this could lead to
If it works, this could point toward a new treatment that slows or shrinks metastatic solid tumors, potentially improving outcomes for patients with advanced cancer.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if metarrestin will effectively shrink tumors. Side effects may occur, and the drug may not work for all cancer types studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
-
University of Kansas
RECRUITINGFairway, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••